Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

Harpoon Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- targeting TriTAC®, for the treatment of SCLC.